Login to Your Account

The 'Ampyra' strikes slack: Phase III stroke bid kaput

By Randy Osborne
Staff Writer

Monday, November 21, 2016

Acorda Therapeutics Inc.'s phase III fizzle in post-stroke walking difficulties of potassium channel blocker Ampyra didn't put much of a dent in the stock, but it made for the second development halt this year and put pressure on the rest of the pipeline.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription